After the third cycle of myeloid-directed therapy, an interesting immunophenotypic shift was observed in which her leukemia cells exhibited increased CD19 and CD7 surface expression but decreased CD13 and CD33 expression (Fig. 4B). The gene discussed is CD33; the disease is leukemia.